WuXi Biologics signs lease for US clinical-stage facility
The Chinese contract development and manufacturing organization (CDMO) has signed a 10-year lease deal for a clinical manufacturing facility in New Jersey, US.
WuXi Biologics will outfit the 66,000-square-foot facility with a total capacity of 6,000L, as well as building process development and quality control labs.
The site will create 100 jobs and add to the company’s rapidly developing manufacturing network in the country.
Last month, the CDMO secured a land deal for its first location in the US, located in Massachusetts, with this facility being both a clinical- and commercial-stage location.
The same month saw WuXi Biologics agree the lease of a 33,00-square-foot process development lab in King of Prussia, Pennsylvania.
This year has seen WuXi Biologics make a concerted effort to expand its physical presence into Western countries, after three deals in the US and the acquisition of its first European drug product facility, in Germany.
The deal saw WuXi Biologics take on Bayer’s facility and become a back-up manufacturer for the latter company’s products.
Though it is WuXi Biologics first drug product facility, it is current constructing a second facility, in Ireland, which will become the world’s largest single-use-focused location.
